Pathogenesis of West Nile virus infection: A balance between virulence, innate and adaptive immunity, and viral evasion

Journal of Virology

Volumn 80, Issue 19, 2006, Pages 9349-9360

  Samuel, Melanie A ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR IMMUNITY; COMPLEMENT SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; RNA VIRUS INFECTION; SHORT SURVEY; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY, NATURAL; WEST NILE FEVER; WEST NILE VIRUS;

WEST NILE VIRUS;

EID: 33748933523     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01122-06     Document Type: Short Survey

References (204)

1. Allison, S. L., J. Schalich, K. Stiasny, C. W. Mandl, and F. X. Heinz. 2001. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 75:4268-4275.
2. Allison, S. L., J. Schalich, K. Stiasny, C. W. Mandl, C. Kunz, and F. X. Heinz. 1995. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J. Virol. 69:695-700.
3. Anderson, J. F., and J. J. Rahal. 2002. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg. Infect. Dis. 8:107-108.
4. + T-cell immunity. J. Virol. 76:3791-3799.
5. Arroyo, J., C. Miller, J. Catalan, G. A. Myers, M. S. Ratterree, D. W. Trent, and T. P. Monath. 2004. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78:12497-12507.
6. Asensio, V. C., J. Maier, R. Milner, K. Boztug, C. Kincaid, M. Moulard, C. Phillipson, K. Lindsley, T. Krucker, H. S. Fox, and I. L. Campbell. 2001. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J. Virol. 75:7067-7077.
7. Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, and G. Trinchieri. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 201:1157-1167.
8. Bakri, S. J., and P. K. Kaiser. 2004. Ocular manifestations of West Nile virus. Curr. Opin. Ophthalmol. 15:537-540.
9. Banet-Noach, C., L. Simanov, and M. Malkinson. 2003. Direct (non-vector) transmission of West Nile virus in geese. Avian Pathol. 32:489-494.
10. Barton, G. M., and R. Medzhitov. 2003. Linking Toll-like receptors to IFN-α/β expression. Nat. Immunol. 4:432-433.
11. Beasley, D. W., and J. G. Aaskov. 2001. Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279:447-458.
12. Beasley, D. W., and A. D. Barrett. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76:13097-13100.
13. Beasley, D. W., L. Li, M. T. Suderman, and A. D. Barrett. 2002. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296:17-23.
14. Beasley, D. W., M. C. Whiteman, S. Zhang, C. Y. Huang, B. S. Schneider, D. R. Smith, G. D. Gromowski, S. Higgs, R. M. Kinney, and A. D. Barrett. 2005. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79:8339-8347.
15. Ben-Nathan, D., I. Huitinga, S. Lustig, N. van Rooijen, and D. Kobiler. 1996. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141:459-469.
16. Ben-Nathan, D., S. Lustig, G. Tam, S. Robinzon, S. Segal, and B. Rager-Zisman. 2003. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188:5-12.
17. Best, S. M., K. L. Morris, J. G. Shannon, S. J. Robertson, D. N. Mitzel, G. S. Park, E. Boer, J. B. Wolfinbarger, and M. E. Bloom. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 79:12828-12839.
18. Bhardwaj, S., M. Holbrook, R. E. Shope, A. D. Barrett, and S. J. Watowich. 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75:4002-4007.
19. Binder, G. K., and D. E. Griffin. 2001. Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science 293:303-306.
20. Bode, A. V., J. J. Sejvar, W. J. Pape, G. L. Campbell, and A. A. Marfin. 2006. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin. Infect. Dis. 42:1234-1240.
21. Brault, A. C., S. A. Langevin, R. A. Bowen, N. A. Panella, B. J. Biggerstaff, B. R. Miller, and K. Nicholas. 2004. Differential virulence of West Nile strains for American crows. Emerg. Infect. Dis. 10:2161-2168.
22. Brenner, W., G. Storch, R. Buller, R. Vij, S. Devine, and J. DiPersio. 2005. West Nile virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance. Bone Marrow Transplant. 36:369-370.
23. Brinton, M. A. 2002. The molecular biology of West Nile virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 56:371-402.
24. Burdeinick-Kerr, R., and D. E. Griffin. 2005. Gamma interferon-dependent, noncytolytic clearance of Sindbis virus infection from neurons in vitro. J. Virol. 79:5374-5385.
25. Busch, M. P. 2006. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg. Infect. Dis. 12:395-402.
26. Byrne, S. N., G. M. Halliday, L. J. Johnston, and N. J. King. 2001. Interleukin-1β but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J. Investig. Dermatol. 117:702-709.
27. Camenga, D. L., N. Nathanson, and G. A. Cole. 1974. Cyclophosphamide- potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J. Infect. Dis. 130:634-641.
28. Carding, S. R., and P. J. Egan. 2002. γδ T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2:336-345.
29. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986.
30. Ceausu, E., S. Erscoiu, P. Calistru, D. Ispas, O. Dorobat, M. Homos, C. Barbulescu, I. Cojocaru, C. V. Simion, C. Cristea, C. Oprea, C. Dumitrescu, D. Duiculescu, I. Marcu, C. Mociornita, T. Stoicev, I. Zolotusca, C. Calomfirescu, R. Rusu, R. Hodrea, S. Geamai, and L. Paun. 1997. Clinical manifestations in the West Nile virus outbreak. Rom. J. Virol. 48:3-11.
31. Cecilia, D., and E. A. Gould. 1991. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization- resistant mutants. Virology 181:70-77.
32. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
33. Cheng, Y., N. J. King, and A. M. Kesson. 2004. Major histocompatibility complex class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in MHC-I up-regulation. J. Infect. Dis. 189:658-668.
34. Chesler, D. A., and C. S. Reiss. 2002. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13:441-454.
35. Chowers, M. Y., R. Lang, F. Nassar, D. Ben-David, M. Giladi, E. Rubinshtein, A. Itzhaki, J. Mishal, Y. Siegman-Igra, R. Kitzes, N. Pick, Z. Landau, D. Wolf, H. Bin, E. Mendelson, S. D. Pitlik, and M. Weinberger. 2001. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg. Infect. Dis. 7:675-678.
36. Chu, J. J., and M. L. Ng. 2004. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J. Virol. 78:10543-10555.
37. 3 integrin mediates virus entry into cells. J. Biol. Chem. 279:54533-54541.
38. Chu, J. J., R. Rajamanonmani, J. Li, R. Bhuvanakantham, J. Lescar, and M. L. Ng. 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86:405-412.
39. Chung, K. M., G. E. Nyhakken, B. S. Thompson, M. J. Engle, A. Marri, D. H. Fremont, and M. S. Diamond. 2006. Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fcγ receptor-dependent and -independent mechanisms. J. Virol. 80:1340-1351.
40. Colombage, G., R. Hall, M. Pavy, and M. Lobigs. 1998. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:151-163.
41. Crance, J. M., N. Scaramozzino, A. Jouan, and D. Garin. 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58:73-79.
42. Crill, W. D., and J. T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
43. Dauphin, G., S. Zientara, H. Zeller, and B. Murgue. 2004. West Nile: worldwide current situation in animals and humans. Comp. Immunol. Microbiol. Infect. Dis. 27:343-355.
44. Davis, C. W., H. Y. Nguyen, S. L. Hanna, M. D. Sanchez, R. W. Doms, and T. C. Pierson. 2006. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 80:1290-1301.
45. Deardorff, E., J. Estrada-Franco, A. C. Brault, R. Navarro-Lopez, A. Campomanes-Cortes, P. Paz-Ramirez, M. Solis-Hernandez, W. N. Ramey, C. T. Davis, D. W. Beasley, R. B. Tesh, A. D. Barrett, and S. C. Weaver. 2006. Introductions of West Nile virus strains to Mexico. Emerg. Infect. Dis. 12:314-318.
46. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
47. Diamond, M. S., E. M. Sitati, L. D. Friend, S. Higgs, B. Shrestha, and M. Engle. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
48. Douglas, M. W., A. M. Kesson, and N. J. King. 1994. CTL recognition of West Nile virus-infected fibroblasts is cell cycle dependent and is associated with virus-induced increases in class 1 MHC antigen expression. Immunology 82:561-570.
49. Egloff, M. P., D. Benarroch, B. Selisko, J. L. Romette, and B. Canard. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21:2757-2768.
50. Eldadah, A. H., and N. Nathanson. 1967. Pathogenesis of West Nile virus encephalitis in mice and rats. II. Virus multiplication, evolution of immunofluorescence, and development of histological lesions in the brain. Am. J. Epidemiol. 86:776-790.
51. Elshuber, S., S. L. Allison, F. X. Heinz, and C. W. Mandl. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84:183-191.
52. Falconar, A. K. 1999. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 144:2313-2330.
53. Farajollahi, A., N. A. Panella, P. Carr, W. Crans, K. Burguess, and N. Komar. 2003. Serologic evidence of West Nile virus infection in black bears (Ursus americanus) from New Jersey. J. Wildl. Dis. 39:894-896.
54. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491-496.
55. Fratkin, J. D., A. A. Leis, D. S. Stokic, S. A. Slavinski, and R. W. Geiss. 2004. Spinal cord neuropathology in human West Nile virus infection. Arch. Pathol. Lab. Med. 128:533-537.
56. Fredericksen, B. L., and M. Gale, Jr. 2006. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J. Virol. 80:2913-2923.
57. Fredericksen, B. L., M. Smith, M. G. Katze, P. Y. Shi, and M. Gale, Jr. 2004. The host response to West Nile virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78:7737-7747.
58. Garcia-Tapia, D., C. M. Loiacono, and S. B. Kleiboeker. 2006. Replication of West Nile virus in equine peripheral blood mononuclear cells. Vet. Immunol. Immunopathol. 110:229-244.
59. Gibbs, S. E., A. E. Ellis, D. G. Mead, A. B. Allison, J. K. Moulton, E. W. Howerth, and D. E. Stallknecht. 2005. West Nile virus detection in the organs of naturally infected blue jays (Cyanoeitta cristata). J. Wildl. Dis. 41:354-362.
60. Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. Diamond, and M. Colonna. 2006. Essential role of mda-5 in type 1 IFN responses to polyriboinosinic:polyribocytidylic acid and enecphalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103:8459-8464.
61. Glass, W. G., J. K. Lim, R. Cholera, A. G. Pletnev, J. L. Gao, and P. M. Murphy. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202: 1087-1098.
62. Glass, W. G., D. H. McDermott, J. K. Lim, S. Lekhong, S. F. Yu, W. A. Frank, J. Pape, R. C. Cheshier, and P. M. Murphy. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203: 35-40.
63. Gollins, S. W., and J. S. Porterfield. 1985. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J. Gen. Virol. 66(Pt. 9):1969-1982.
64. Gollins, S. W., and J. S. Porterfield. 1986. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321:244-246.
65. Gollins, S. W., and J. S. Porterfield. 1986. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. J. Gen. Virol. 67(Pt. 9):1941-1950.
66. Gould, L. H., J. Sui, H. Foellmer, T. Oliphant, T. Wang, M. Ledizet, A. Murakami, K. Noonan, C. Lambeth, K. Kar, J. F. Anderson, A. M. de Silva, M. S. Diamond, R. A. Koski, W. A. Marasco, and E. Fikrig. 2005. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79:14606-14613.
67. Granwehr, B. P., K. M. Lillibridge, S. Higgs, P. W. Mason, J. F. Aronson, G. A. Campbell, and A. D. Barrett. 2004. West Nile virus: where are we now? Lancet Infect. Dis. 4:547-556.
68. Griffin, D. E. 2003. Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol. 3:493-502.
69. Guarner, J., W. J. Shieh, S. Hunter, C. D. Paddock, T. Morken, G. L. Campbell, A. A. Martin, and S. R. Zaki. 2004. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum. Pathol. 35:983-990.
70. Guirakhoo, F., F. X. Heinz, C. W. Mandl, H. Holzmann, and C. Kunz. 1991. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 72(Pt. 6):1323-1329.
71. Guo, J. T., J. Hayashi, and C. Seeger. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79:1343-1350.
72. Halevy, M., Y. Akov, D. Ben-Nathan, D. Kobiler, B. Lachmi, and S. Lustig. 1994. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch. Virol. 137:355-370.
73. Hanna, S. L., T. C. Pierson, M. D. Sanchez, A. A. Ahmed, M. M. Murtadha, and R. W. Doms. 2005. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 79:13262-13274.
74. + T cell response to infection. Curr. Opin. Immunol. 14:360-365.
75. Hayes, E. B., N. Komar, R. S. Nasci, S. P. Montgomery, D. R. O'Leary, and G. L. Campbell. 2005. Epidemiology and transmission dynamics of West Nile virus disease. Emerg. Infect. Dis. 11:1167-1173.
76. Hayes, E. B., J. J. Sejvar, S. R. Zaki, R. S. Lanciotti, A. V. Bode, and G. L. Campbell. 2005. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11:1174-1179.
77. Herzer, K., C. S. Falk, J. Encke, S. T. Eichhorst, A. Ulsenheimer, B. Seliger, and P. H. Krammer. 2003. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J. Virol. 77:8299-8309.
78. Hunsperger, E. A., and J. T. Roehrig. 2006. Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J. Neurovirol. 12:129-139.
79. Jacobson, E. R., P. E. Ginn, J. M. Troutman, L. Farina, L. Stark, K. Klenk, K. L. Burkhalter, and N. Komar. 2005. West Nile virus infection in farmed American alligators (Alligator mississippiensis) in Florida. J. Wildl. Dis. 41:96-106.
80. Jerzak, G., K. A. Bernard, L. D. Kramer, and G. D. Ebel. 2005. Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J. Gen. Virol. 86:2175-2183.
81. Johnson, R. T. 1998. Viral infections of the nervous system, 2nd ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
82. Jupp, P. G. 2001. The ecology of West Nile virus in South Africa and the occurrence of outbreaks in humans. Ann. N. Y. Acad. Sci. 951:143-152.
83. Kang, D. C., R. V. Gopalkrishnan, Q. Wu, E. Jankowsky, A. M. Pyle, and P. B. Fisher. 2002. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. USA 99:637-642.
84. 83a. Kaufmann, B., G. E. Nybakken, P. R. Chipman, W. Zhang, M. S. Diamond, D. H. Fremont, R. J. Kuhn, and M. G. Rossmann. West Nile virus in complex with a Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. USA, in press.
85. 83b. Keller, B. C., B. L. Fredericksen, M. A. Samuel, R. E. Mock, P. W. Mason, M. S. Diamond, and M. Gale, Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80:9424-9434.
86. Kesson, A. M., R. V. Blanden, and A. Mullbacher. 1987. The primary in vivo murine cytotoxic T cell response to the flavivirus, West Nile. J. Gen. Virol. 68(Pt. 7):2001-2006.
87. Kesson, A. M., and N. J. King. 2001. Transcriptional regulation of major histocompatibility complex class I by flavivirus West Nile is dependent on NF-κB activation. J. Infect. Dis. 184:947-954.
88. Khromykh, A. A., P. L. Sedlak, K. J. Guyatt, R. A. Hall, and E. G. Westaway. 1999. Efficient trans-complementation of the flavivirus Kunjin NS5 protein but not of the NS1 protein requires its coexpression with other components of the viral replicase. J. Virol. 73:10272-10280.
89. Khromykh, A. A., P. L. Sedlak, and E. G. Westaway. 2000. cis- and trans-acting elements in flavivirus RNA replication. J. Virol. 74:3253-3263.
90. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97:2731-2736.
91. King, N. J., and A. M. Kesson. 2003. Interaction of flaviviruses with cells of the vertebrate host and decoy of the immune response. Immunol. Cell Biol. 81:207-216.
92. King, N. J., and A. M. Kesson. 1988. Interferon-independent increases in class I major histocompatibility complex antigen expression follow flavivirus infection. J. Gen. Virol. 69(Pt. 10):2535-2543.
93. King, N. J., L. E. Maxwell, and A. M. Kesson. 1989. Induction of class I major histocompatibility complex antigen expression by West Nile virus on gamma interferon-refractory early murine trophoblast cells. Proc. Natl. Acad. Sci. USA 86:911-915.
94. Klee, A. L., B. Maidin, B. Edwin, I. Poshni, F. Mostashari, A. Fine, M. Layton, and D. Nash. 2004. Long-term prognosis for clinical West Nile virus infection. Emerg. Infect. Dis. 10:1405-1411.
95. + T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79:11457-11466.
96. Kleinschmidt-DeMasters, B. K., B. A. Marder, M. E. Levi, S. P. Laird, J. T. McNutt, E. J. Escott, G. T. Everson, and K. L. Tyler. 2004. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch. Neurol. 61: 1210-1220.
97. Komar, N., and G. G. Clark. 2006. West Nile virus activity in Latin America and the Caribbean. Rev. Panam. Salud Publica 19:112-117.
98. Komar, N., S. Langevin, S. Hinten, N. Nemeth, E. Edwards, D. Hettler, B. Davis, R. Bowen, and M. Bunning. 2003. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg. Infect. Dis. 9:311-322.
99. Kramer, L. D., and K. A. Bernard. 2001. West Nile virus infection in birds and mammals. Ann. N. Y. Acad. Sci. 951:84-93.
100. Kramer-Hammerle, S., I. Rothenaigner, H. Wolff, J. E. Bell, and R. Brack-Werner. 2005. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 111:194-213.
101. Kreil, T. R., and M. M. Eibl. 1996. Nitric oxide and viral infection: NO antiviral activity against a flavivirus in vitro, and evidence for contribution to pathogenesis in experimental infection in vivo. Virology 219:304-306.
102. Kulkarni, A. B., A. Mullbacher, and R. V. Blanden. 1991. In vitro T-cell proliferative response to the flavivirus, West Nile. Viral Immunol. 4:73-82.
103. Lanciotti, R. S., G. D. Ebel, V. Deubel, A. J. Kerst, S. Murri, R. Meyer, M. Bowen, N. McKinney, W. E. Morrill, M. B. Crabtree, L. D. Kramer, and J. T. Roehrig. 2002. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298:96-105.
104. Lanciotti, R. S., J. T. Roehrig, V. Deubel, J. Smith, M. Parker, K. Steele, B. Crise, K. E. Volpe, M. B. Crabtree, J. H. Scherret, R. A. Hall, J. S. MacKenzie, C. B. Cropp, B. Panigrahy, E. Ostlund, B. Schmitt, M. Malkinson, C. Banet, J. Weissman, N. Komar, H. M. Savage, W. Stone, T. McNamara, and D. J. Gubler. 1999. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:2333-2337.
105. Lane, T. E., V. C. Asensio, N. Yu, A. D. Paoletti, I. L. Campbell, and M. J. Buchmeier. 1998. Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J. Immunol. 160:970-978.
106. Langevin, S. A., A. C. Brault, N. A. Panella, R. A. Bowen, and N. Komar. 2005. Variation in virulence of West Nile virus strains for house sparrows (Passer domesticus). Am. J. Trop. Med. Hyg. 72:99-102.
107. Le Bon, A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, and D. F. Tough. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176:2074-2078.
108. Ledizet, M., K. Kar, H. G. Foellmer, T. Wang, S. L. Bushmich, J. F. Anderson, E. Fikrig, and R. A. Koski. 2005. A recombinant envelope protein vaccine against West Nile virus. Vaccine 23:3915-3924.
109. Li, J., R. Bhuvanakantham, J. Howe, and M. L. Ng. 2006. The glycosylation site in the envelope protein of West Nile virus (Sarafend) plays an important role in replication and maturation processes. J. Gen. Virol. 87:613-622.
110. Li, L., A. D. Barrett, and D. W. Beasley. 2005. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335:99-105.
111. Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright. 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202:885-890.
112. Lin, R.-J., B.-L. Chang, H.-P. Yu, C.-L. Liao, and Y.-L. Lin. 2006. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J. Virol. 80: 5908-5918.
113. Lin, R.-J., C.-L. Liao, E. Lin, and Y.-L. Lin. 2004. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J. Virol. 78:9285-9294.
114. Lin, Y.-L., Y.-L. Huang, S.-H. Ma, C.-T. Yeh, S.-Y. Chiou, L.-K. Chen, and C.-L. Liao. 1997. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J. Virol. 71:5227-5235.
115. Liu, W. J., H. B. Chen, and A. A. Khromykh. 2003. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77:7804-7813.
116. Liu, W. J., X. J. Wang, D. C. Clark, M. Lobigs, R. A. Hall, and A. A. Khromykh. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80:2396-2404.
117. Liu, W. J., X. J. Wang, V. V. Mokhonov, P.-Y. Shi, R. Randall, and A. A. Khromykh. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79:1934-1942.
118. Liu, Y., R. V. Blanden, and A. Mullbacher. 1989. Identification of cytolytic lymphocytes in West Nile virus-infected murine central nervous system. J. Gen. Virol. 70(Pt. 3):565-573.
119. Liu, Y., N. King, A. Kesson, R. V. Blanden, and A. Mullbacher. 1988. West Nile virus infection modulates the expression of class I and class II MHC antigens on astrocytes in vitro. Ann. N. Y. Acad. Sci. 540:483-485.
120. Macdonald, J., J. Tonry, R. A. Hall, B. Williams, G. Palacios, M. S. Ashok, O. Jabado, D. Clark, R. B. Tesh, T. Briese, and W. I. Lipkin. 2005. NS1 protein secretion during the acute phase of West Nile virus infection. J. Virol. 79:13924-13933.
121. Mackenzie, J. M., and E. G. Westaway. 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J. Virol. 75:10787-10799.
122. Mackenzie, J. S., D. J. Gubler, and L. R. Petersen. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10:S98-S109.
123. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-530.
124. Mashimo, T., M. Lucas, D. Simon-Chazottes, M. P. Frenkiel, X. Montagutelli, P. E. Ceccaldi, V. Deubel, J. L. Guenet, and P. Despres. 2002. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. USA 99:11311-11316.
125. Mason, P. W. 1989. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 169:354-364.
126. Matsumoto, M., K. Funami, M. Tanabe, H. Oshiumi, M. Shingai, Y. Seto, A. Yamamoto, and T. Seya. 2003. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171:3154-3162.
127. Mehlhop, E., and M. S. Diamond. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
128. Mehlhop, E., K. Whitby, T. Oliphant, A. Marri, M. Engle, and M. S. Diamond. 2005. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 79: 7466-7477.
129. Meurs, E. F., Y. Watanabe, S. Kadereit, G. N. Barber, M. G. Katze, K. Chong, B. R. Williams, and A. G. Hovanessian. 1992. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66:5805-5814.
130. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
131. Monath, T. P., C. B. Cropp, and A. K. Harrison. 1983. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab. Investig. 48:399-410.
132. Monath, T. P., J. Liu, N. Kanesa-Thasan, G. A. Myers, R. Nichols, A. Deary, K. McCarthy, C. Johnson, T. Ermak, S. Shin, J. Arroyo, F. Guirakhoo, J. S. Kennedy, F. A. Ennis, S. Green, and P. Bedford. 2006. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103:6694-6699.
133. Mukhopadhyay, S., R. J. Kuhn, and M. G. Rossmann. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13-22.
134. Muñoz-Jordán, J. L., M. Laurent-Rolle, J. Ashour, L. Martínez-Sobrido, M. Ashok, W. I. Lipkin, and A. García-Sastre. 2005. Inhibition of alpha/ beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004-8013.
135. Muñoz-Jordán, J. L., G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. García-Sastre. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 100:14333-14338.
136. Murray, K., S. Baraniuk, M. Resnick, R. Arafat, C. Kilborn, K. Cain, R. Shallenberger, T. L. York, D. Martinez, J. S. Hellums, D. Hellums, M. Malkoff, N. Elgawley, W. McNeely, S. A. Khuwaja, and R. B. Tesh. 4 May 2006. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol. Infect. 134:1-8. [Epub ahead of print.]
137. Nash, D., F. Mostashari, A. Fine, J. Miller, D. O'Leary, K. Murray, A. Huang, A. Rosenberg, A. Greenberg, M. Sherman, S. Wong, and M. Layton. 2001. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344:1807-1814.
138. Nathanson, N., and G. A. Cole. 1970. Immunosuppression and experimental virus infection of the nervous system. Adv. Virus Res. 16:397-448.
139. Nybakken, G. E., T. Oliphant, S. Johnson, S. Burke, M. S. Diamond, and D. H. Fremont. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-769.
140. O'Leary, D. R., A. A. Marfin, S. P. Montgomery, A. M. Kipp, J. A. Lehman, B. J. Biggerstaff, V. L. Elko, P. D. Collins, J. E. Jones, and G. L. Campbell. 2004. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis. 4:61-70.
141. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11(5):522-530.
142. Omalu, B. I., A. A. Shakir, G. Wang, W. I. Lipkin, and C. A. Wiley. 2003. Fatal fulminant pan-meningo-polioencephalitis due to West Nile virus. Brain Pathol. 13:465-472.
143. Ozkul, A., Y. Yildirim, D. Pinar, A. Akcali, V. Yilmaz, and D. Colak. 2005. Serological evidence of West Nile virus (WNV) in mammalian species in Turkey. Epidemiol. Infect. 134(4):826-829.
144. Paddock, C. D., W. L. Nicholson, J. Bhatnagar, C. S. Goldsmith, P. W. Greer, E. B. Hayes, J. A. Risko, C. Henderson, C. G. Blackmore, R. S. Lanciotti, G. L. Campbell, and S. R. Zaki. 2006. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin. Infect. Dis. 42:1527-1535.
145. Palma, J. P., and B. S. Kim. 2004. The scope and activation mechanisms of chemokine gene expression in primary astrocytes following infection with Theiler's virus. J. Neuroimmunol. 149:121-129.
146. Panella, N. A., A. J. Kerst, R. S. Lanciotti, P. Bryant, B. Wolf, and N. Komar. 2001. Comparative West Nile virus detection in organs of naturally infected American crows (Corvus brachyrhynchos). Emerg. Infect. Dis. 7:754-755.
147. Parquet, M. C., A. Kumatori, F. Hasebe, K. Morita, and A. Igarashi. 2001. West Nile virus-induced bax-dependent apoptosis. FEBS Lett. 500:17-24.
148. Perelygin, A. A., S. V. Scherbik, I. B. Zhulin, B. M. Stockman, Y. Li, and M. A. Brinton. 2002. Positional cloning of the murine flavivirus resistance gene. Proc. Natl. Acad. Sci. USA 99:9322-9327.
149. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202:8-32.
150. Petersen, L. R., and A. A. Marfin. 2002. West Nile virus: a primer for the clinician. Ann. Intern. Med. 137:173-179.
151. Petersen, L. R., and J. T. Roehrig. 2001. West Nile virus: a reemerging global pathogen. Emerg. Infect. Dis. 7:611-614.
152. Pincus, S., P. W. Mason, E. Konishi, B. A. Fonseca, R. E. Shope, C. M. Rice, and E. Paoletti. 1992. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187:290-297.
153. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5:375-386.
154. Pruitt, A. A. 2004. Central nervous system infections in cancer patients. Semin. Neurol. 24:435-452.
155. Ramanathan, M. P., J. A. Chambers, P. Pankhong, M. Chattergoon, W. Attatippaholkun, K. Dang, N. Shah, and D. B. Weiner. 2006. Host cell killing by the West Nile virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology 345:56-72.
156. + T cells and viral persistence. J. Virol. 76:2217-2224.
157. Rodriguez, M., L. J. Zoecklein, C. L. Howe, K. D. Pavelko, J. D. Gamez, S. Nakane, and L. M. Papke. 2003. Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial Theiler's murine encephalomyelitis virus infection. J. Virol. 77:12252-12265.
158. Roehrig, J. T., R. A. Bolin, and R. G. Kelly. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328.
159. Root, J. J., J. S. Hall, R. G. McLean, N. L. Marlenee, B. J. Beaty, J. Gansowski, and L. Clark. 2005. Serologic evidence of exposure of wild mammals to flaviviruses in the central and eastern United States. Am. J. Trop. Med. Hyg. 72:622-630.
160. Roozendaal, R., and M. C. Carroll. 2006. Emerging patterns in complement-mediated pathogen recognition. Cell 125:29-32.
161. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:323-370.
162. Samuel, M. A., and M. S. Diamond. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361.
163. Samuel, M. A., K. Whitby, B. C. Keller, A. Marri, W. Barchet, B. R. G. Williams, R. H. Silverman, M. Gale, Jr., and M. S. Diamond. 2006. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80:7009-7019.
164. Scherbik, S. V., J. M. Paranjape, B. M. Stockman, R. H. Silverman, and M. A. Brinton. 2006. RNase L plays a role in the antiviral response to West Nile virus. J. Virol. 80:2987-2999.
165. Scherret, J. H., J. S. Mackenzie, R. A. Hall, V. Deubel, and E. A. Gould. 2002. Phytogeny and molecular epidemiology of West Nile and Kunjin viruses. Curr. Top. Microbiol. Immunol. 267:373-390.
166. Scholle, F., and P. W. Mason. 2005. West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment. Virology 342:77-87.
167. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-189.
168. Sejvar, J. J. 2006. West Nile virus-associated flaccid paralysis outcome. Emerg. Infect. Dis. 12:514-516.
169. Sejvar, J. J., M. B. Haddad, B. C. Tierney, G. L. Campbell, A. A. Marfin, J. A. Van Gerpen, A. Fleischauer, A. A. Leis, D. S. Stokic, and L. R. Petersen. 2003. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290:511-515.
170. Sejvar, J. J., A. A. Leis, D. S. Stokic, J. A. Van Gerpen, A. A. Marfin, R. Webb, M. B. Haddad, B. C. Tierney, S. A. Slavinski, J. L. Polk, V. Dostrow, M. Winkelmann, and L. R. Petersen. 2003. Acute flaccid paralysis and West Nile virus infection. Emerg. Infect. Dis. 9:788-793.
171. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.
172. Shirato, K., H. Miyoshi, A. Goto, Y. Ako, T. Ueki, H. Kariwa, and I. Takashima. 2004. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol. 85:3637-3645.
173. + T cells in control of West Nile virus infection. J. Virol. 78:8312-8321.
174. Shrestha, B., D. Gottlieb, and M. S. Diamond. 2003. Infection and injury of neurons by West Nile encephalitis virus. J. Virol. 77:13203-13213.
175. + T cells require perform to clear West Nile virus from infected neurons. J. Virol. 80:119-129.
176. Shrestha, B., T. Wang, M. A. Samuel, K. Whitby, J. Craft, E. Fikrig, and M. S. Diamond. 2006. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80:5338-5348.
177. Silverman, R. H. 1997. 2-5A-dependent RNase L: a regulated endoribonuclease in the interferon system, p. 115. In E. G. D'Alessio and J. F Riordan (ed.), Ribonuclease: structure and function. Academic Press, Inc., New York, N.Y.
178. Steele, C. R., D. E. Oppenheim, and A. C. Hayday. 2000. γδ T cells: non-classical ligands for non-classical cells. Curr. Biol. 10:R282-R285.
179. Tesh, R. B., J. Arroyo, A. P. Travassos Da Rosa, H. Guzman, S. Y. Xiao, and T. P. Monath. 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8:1392-1397.
180. Tesh, R. B., M. Siirin, H. Guzman, A. P. Travassos da Rosa, X. Wu, T. Duan, H. Lei, M. R. Nunes, and S. Y. Xiao. 2005. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J. Infect. Dis. 192:287-295.
181. Tsai, T. F., F. Popovici, C. Cernescu, G. L. Campbell, and N. I. Nedelcu. 1998. West Nile encephalitis epidemic in southeastern Romania. Lancet 352:767-771.
182. Vargin, V. V., and B. F. Semenov. 1986. Changes of natural killer cell activity in different mouse lines by acute and asymptomatic flavivirus infections. Acta Virol. 30:303-308.
183. Vazquez, S., M. G. Guzman, G. Guillen, G. Chinea, A. B. Perez, M. Pupo, R. Rodriguez, O. Reyes, H. E. Garay, I. Delgado, G. Garcia, and M. Alvarez. 2002. Immune response to synthetic peptides of dengue prM protein. Vaccine 20:1823-1830.
184. Volk, D. E., D. W. Beasley, D. A. Kallick, M. R. Holbrook, A. D. Barrett, and D. G. Gorenstein. 2004. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J. Biol. Chem. 279:38755-38761.
185. Wang, T., J. F. Anderson, L. A. Magnarelli, S. J. Wong, R. A. Koski, and E. Fikrig. 2001. Immunization of mice against West Nile virus with recombinant envelope protein. J. Immunol. 167:5273-5277.
186. Wang, T., Y. Gao, E. Scully, C. T. Davis, J. F. Anderson, T. Welte, M. Ledizet, R. Koski, J. A. Madri, A. D. Barrett, Z. Yin, J. Craft, and E. Fikrig. 2006. γ-δ T cells facilitate adaptive immunity against West Nile virus. J. Immunol. 177:1825-1832.
187. Wang, T., E. Scully, Z. Yin, J. H. Kim, S. Wang, J. Yan, M. Mamula, J. F. Anderson, J. Craft, and E. Fikrig. 2003. IFN-γ-producing γδ T cells help control murine West Nile virus infection. J. Immunol. 171:2524-2531.
188. Wang, T., T. Town, L. Alexopoulou, J. F. Anderson, E. Fikrig, and R. A. Flavell. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-1373.
189. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77:13323-13334.
190. Wang, Y., M. Lobigs, E. Lee, and A. Mullbacher. 2004. Exocytosis and Fas mediated cytolytic mechanisms exert protection from West Nile virus induced encephalitis in mice. Immunol. Cell Biol. 82:170-173.
191. Watson, J. T., P. E. Pertel, R. C. Jones, A. M. Siston, W. S. Paul, C. C. Austin, and S. I. Gerber. 2004. Clinical characteristics and functional outcomes of West Nile fever. Ann. Intern. Med. 141:360-365.
192. Weaver, S. C., and A. D. Barrett. 2004. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2:789-801.
193. Winkler, G., S. E. Maxwell, C. Ruemmler, and V. Stollar. 1989. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. Virology 171:302-305.
194. Winkler, G., V. B. Randolph, G. R. Cleaves, T. E. Ryan, and V. Stollar. 1988. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 162:187-196.
195. Wu, S. C., W. C. Lian, L. C. Hsu, and M. Y. Liau. 1997. Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res. 51:173-181.
196. Wunschmann, A., J. Shivers, L. Carroll, and J. Bender. 2004. Pathological and immunohistochemical findings in American crows (Corvus brachyrhynchos) naturally infected with West Nile virus. J. Vet. Diagn. Investig. 16: 329-333.
197. Xiao, S. Y., H. Guzman, H. Zhang, A. P. Travassos da Rosa, and R. B. Tesh. 2001. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg. Infect. Dis. 7:714-721.
198. Yakub, I., K. M. Lillibridge, A. Moran, O. Y. Gonzalez, J. Belmont, R. A. Gibbs, and D. J. Tweardy. 2005. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L in patients hospitalized with West Nile virus infection. J. Infect. Dis. 192:1741-1748.
199. Yang, J. S., J. J. Kim, D. Hwang, A. Y. Choo, K. Dang, H. Maguire, S. Kudchodkar, M. P. Ramanathan, and D. B. Weiner. 2001. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J. Infect. Dis. 184:809-816.
200. Yang, J. S., M. P. Ramanathan, K. Muthumani, A. Y. Choo, S. H. Jin, Q. C. Yu, D. S. Hwang, D. K. Choo, M. D. Lee, K. Dang, W. Tang, J. J. Kim, and D. B. Weiner. 2002. Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg. Infect. Dis. 8:1379-1384.
201. Yim, R., K. M. Posfay-Barbe, D. Nolt, G. Fatula, and E. R. Wald. 2004. Spectrum of clinical manifestations of West Nile virus infection in children. Pediatrics 114:1673-1675.
202. Yoneyama, M., M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, K. Taira, E. Foy, Y. M. Loo, M. Gale, Jr., S. Akira, S. Yonehara, A. Kato, and T. Fujita. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175: 2851-2858.
203. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.
204. Yusof, R., S. Clum, M. Wetzel, H. M. Murthy, and R. Padmanabhan. 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 275:9963-9969.